Peptide therapeutics: navigating development with DMPK & toxicology

What will you learn?

• Understand key DMPK challenges for peptide therapeutics, including absorption barriers and formulation impact
• Explore bioanalytical strategies for accurate peptide quantification and immunogenicity evaluation
• Learn how peptide toxicology differs from small molecules and how to design effective safety studies
• Discover how integrated DMPK, bioanalysis and toxicology approaches streamline development and reduce risk
• Gain insights from real-world case examples to support smarter study design and regulatory readiness

Who may this interest?

• Bioanalytical scientists working with peptide therapeutics in pharmaceutical research and development
• Business executives in pharmaceutical companies with peptide products or projects in their development pipelines
• R&D professionals involved in peptide therapeutic discovery, development and commercialization pathways

Jianping Sun 
Study Director, DMPK
WuXi AppTec (Shanghai, China)

Jianping Sun, Director at WuXi AppTec, leads the DMPK Study Director team. With 5 years of in vitro ADME lab experience and over 10 years in DMPK project management, he specializes in global IND strategies. Jianping has led over 60 IND projects across small molecules, PROTACs, peptides, oligonucleotides, antibodies and antibody-drug conjugates (ADCs).

Jing Huang
Director, LC–MS & Toxicology
WuXi AppTec

Jing Huang leads the LC–MS Bioanalysis team in the Toxicology Department at WuXi AppTec. She is responsible for team management and ensuring the delivery of high-quality bioanalytical analysis data using LC–MS/MS for IND-enabling and post-IND programs. With more than 13 years of experience in regulated bioanalysis, Jing has a comprehensive understanding of small molecule drug analysis and various new drug modalities, such as peptides, antibodies, ADCs, oligonucleotides and lipid nanoparticles. She earned her Master’s degree in analytical chemistry from Central China Normal University (Wuhan, China) and provides innovative solutions in bioanalysis for clients worldwide.

Zhimei Wang
Director, Testing Division Toxicology Department
WuXi AppTec

Zhimei Wang leads the Study Director Group for WuXi AppTec’s toxicology department, Nantong site. With more than 14 years of non-clinical drug safety evaluation, she has gained extensive experience in non-clinical research across various fields, including small molecules, peptides, oligonucleotides, proteins, antibody/prodrug/ADC, LNP, viral and cell therapy products. Zhimei provides technical support and assists in safety evaluation studies for IND and NDA/BLA submissions. In 2023, she obtained a Diplomate of the American Board of Toxicology certification.